Discovery of a potent and selective hetero-bivalent AChE inhibitor via bioisosteric replacement

Molecular Informatics

Volumn 30, Issue 2-3, 2011, Pages 133-136

  Nicolotti, Orazio ^a   Pisani, Leonardo ^a   Catto, Marco ^a   Leonetti, Francesco ^a   Giangreco, Ilenia ^a   Stefanachi, Angela ^a   Carotti, Angelo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Alzheimer's disease; Bioisosteric replacement; Dual binding site AChE inhibitors; Selective hetero bivalent acetylcholinesterase inhibitors

Indexed keywords

BINDING SITES;

ACETYLCHOLINESTERASE INHIBITORS; ALZHEIMERS DISEASE; BINDING-SITES; BIOISOSTERIC REPLACEMENT; DUAL BINDING SITE ACHE INHIBITOR; SELECTIVE HETERO-BIVALENT ACETYLCHOLINESTERASE INHIBITOR;

NEURODEGENERATIVE DISEASES;

3 [4 (3 DIMETHYLAMINO 5 HYDROXY PHENOXY)BUTOXY] 6,7 DIMETHOXY CHROMEN 2 ONE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; CHROMENE DERIVATIVE; COUMARIN; DONEZEPIL; NOOTROPIC AGENT; QUINOLONE; UNCLASSIFIED DRUG;

BINDING AFFINITY; CONFERENCE PAPER; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; IC 50; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROCESS OPTIMIZATION;

EID: 79958824234     PISSN: 18681743     EISSN: 18681751     Source Type: Journal    
DOI: 10.1002/minf.201000126     Document Type: Conference Paper

References (20)

1. B. A. Krueger, A. Dietrich, K. H. Baringhau, G. Schneider, Comb. Chem. High Throughput Screen. 2009, 12, 383-396.
2. H. Mauser, W. Guba, Curr. Opin. Drug Discov. Devel. 2008, 11, 65-74.
3. H. J. Böhm, A. Flohr, M. Stahl, Drug Discov. Today 2004, 1, 217-224.
4. P. Maass, T. Schulz-Gasch, M. Stahl, M. Rarey, J. Chem. Inf. Model, 2007, 47, 390-399.
5. L. Teuber, F. Watjen, L. H. Jensen, Curr. Pharm. Des. 1999, 5, 317-343.
6. J. W. Kebabian, Drug Discov. Today, 1999, 2, 333-340.
7. D. Lednicer, Curr. Med. Chem. 2002, 9, 1457-1461.
8. E. Ongini, A. Monopoli, B. Cacciari, P. G. Baraldi, Farmaco 2001, 56, 87-90.
9. E. Proschak, H. Zettl, Y. Tanrikulu, M. Weisel, J. M. Kriegl, O. Rau, M. Schubert-Zsilavecz, G. Schneider, ChemMedChem 2009, 4, 41-44.
10. P. Ertl, Curr. Opin. Drug. Discov. Devel. 2007, 10, 281-288.
11. F. Leonetti, M. Catto, O. Nicolotti, L. Pisani, A. Cappa, A. Stefanachi, A. Carotti, Bioorg. Med. Chem. 2008, 16, 7450-7456.
12. L. Pisani, M. Catto, I. Giangreco, F. Leonetti, O. Nicolotti, A. Stefanachi, S. Cellamare, A. Carotti, ChemMedChem. 2010, 5, 1616-1630.
13. A. Saxena, A. M. Redman, X. X. Jiang, B. P. Lockridge, B. P. Doctor, Biochemistry 1997, 36, 14642-14651.
14. N. Tsuno, Expert. Rev. Neurother. 2009, 9, 591-598.
15. M. H. Mohajeri, G. Leuba, Brain Res. Bull. 2009, 80, 315-325.
16. Y. C. Martin, J. Comput. Aided. Mol. Des. 2009, 23, 693-704.
17. J. Sadowski, J. Gasteiger, G. M. Klebe, J. Chem. Inf. Comput. Sci. 1994, 34, 1000-1008.
18. M. L. Verdonk, J. C. Cole, M. J. Hartshorn, C. W. Murray, R. D. Taylor, Proteins 2003, 52, 609-623.
19. M. Olah, M. Mracec, L. Ostopovici, R. Rad, A. Bora, N. Hadaruga, I. Olah, M. Banda, Z. Simon, M. Mracec, T. I. Oprea, WOMBAT: World of Molecular Bioactivity, in Chemoinformatics in Drug Discovery, (Ed: T. I. Oprea), Wiley-VCH, New York, 2004, 223-239.
20. B. V. Rama Sastry in Burger's Medicinal Chemistry and Drug Discovery 6th ed., (Ed: D. J. Abraham), Wiley, New York, 2003, 109-166.